Blogging Capital Journal San Diego 
Xconomy
JULY 26, 2016
Adding to the confusion, the most-recent MoneyTree Report on San Diego venture capital activity shows that Ostendo raised almost $10 million in VC funding during the second quarter. Razi, Bussel, and Dull are also on the board of Ingenu, the San Diego wireless technology company known previously as On-Ramp Wireless.
Xconomy
JUNE 12, 2018
He’s the CEO of San Diego medical device startup Tear Film Innovations, which recently raised a. Come to think of it, do your eyes feel dry? Some eye doctors are finding more cases of dry eye in young adults, and even children. That has Rob Thornill seeing opportunity. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
AUGUST 17, 2016
Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China.
Xconomy
SEPTEMBER 27, 2016
Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).
Xconomy
SEPTEMBER 7, 2016
San Diego-based Retrophin said that its drug, sparsentan, outperformed another drug sometimes used to manage a rare kidney disease, called focal segmental glomerulosclerosis (FSGS), in a Phase 2 clinical trial. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. on the Nasdaq.
Xconomy
AUGUST 16, 2016
A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. Losses in over-capitalized “vintage years” over the last two decades have left institutional investors (e.g.
Xconomy
JULY 17, 2020
In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook.
Expert insights. Personalized for you.
40 
Let's personalize your content